Senti Biosciences Inc
SNTI1.700USD
+0.020+1.19%
交易中 （美東）報價延遲15分鐘
44.21M總市值
虧損本益比TTM
關於 Senti Biosciences Inc 公司
Senti Biosciences, Inc. 是一家臨牀階段的生物技術公司。該公司正在利用其基因迴路平臺技術爲患有無法治癒的疾病的患者開發細胞和基因療法。該公司專注於針對腫瘤適應症的現成 CAR-NK 細胞療法項目。其主要候選產品 SENTI-202 是一種潛在的邏輯門控現成 CAR-NK 細胞療法，旨在選擇性靶向和消除表達 CD33 和/或 FLT3 的血液系統惡性腫瘤，包括急性髓細胞白血病，同時保留健康的骨髓細胞。其第二個臨牀開發項目是 SENTI-301A，這是一種多臂現成的健康供體衍生 CAR-NK 細胞療法。SENTI-202 旨在使用邏輯門控基因迴路整合三種嵌合蛋白並通過單個逆轉錄病毒遞送。 SENTI-301A 是一種多臂現成的健康供體衍生的 CAR-NK 細胞療法，旨在治療晚期 GPC3 陽性腫瘤。
公司簡介
公司代碼SNTI
公司名稱Senti Biosciences Inc
上市日期May 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
員工數量34
證券類型Ordinary Share
年結日May 26
公司地址2 Corporate Drive, First Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94080
電話16502392030
網址https://www.sentibio.com/
公司代碼SNTI
上市日期May 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Feng Hsiung
Mr. Feng Hsiung
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Celadon Partners SPV 24
37.49%
New Enterprise Associates (NEA)
14.48%
Bayer HealthCare LLC
10.77%
PharmaEssentia Corp.
8.09%
Armistice Capital LLC
5.52%
Other
23.65%
持股股東
持股股東
佔比
Celadon Partners SPV 24
37.49%
New Enterprise Associates (NEA)
14.48%
Bayer HealthCare LLC
10.77%
PharmaEssentia Corp.
8.09%
Armistice Capital LLC
5.52%
Other
23.65%
股東類型
持股股東
佔比
Corporation
56.35%
Venture Capital
14.48%
Hedge Fund
8.93%
Investment Advisor
4.06%
Individual Investor
0.85%
Investment Advisor/Hedge Fund
0.74%
Other
14.58%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
59
22.28M
85.42%
+16.91M
2025Q1
61
32.06M
123.04%
+28.81M
2024Q4
55
2.74M
57.01%
+442.53K
2024Q3
56
2.03M
44.31%
-591.63K
2024Q2
59
2.00M
43.68%
-736.88K
2024Q1
91
2.11M
47.03%
-1.57M
2023Q4
97
2.11M
47.62%
-1.61M
2023Q3
101
2.43M
55.03%
-1.49M
2023Q2
105
2.45M
55.45%
-1.56M
2023Q1
104
2.49M
56.56%
-1.49M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Celadon Partners SPV 24
9.78M
37.49%
+9.78M
--
Mar 18, 2025
New Enterprise Associates (NEA)
3.78M
14.48%
+3.33M
+753.02%
Mar 31, 2025
Bayer HealthCare LLC
2.81M
10.77%
+2.22M
+377.99%
Mar 10, 2025
PharmaEssentia Corp.
2.11M
8.09%
--
--
Apr 28, 2025
Armistice Capital LLC
1.44M
5.52%
+903.80K
+168.62%
Mar 31, 2025
Nantahala Capital Management, LLC
888.00K
3.4%
+378.72K
+74.36%
Mar 31, 2025
Heights Capital Management, Inc.
750.00K
2.88%
+750.00K
--
Mar 31, 2025
8VC GP I, LLC
253.75K
0.97%
--
--
Mar 31, 2025
Lu (Timothy K M.D., Ph.D.)
161.63K
0.62%
--
--
Apr 28, 2025
The Vanguard Group, Inc.
154.14K
0.59%
+56.67K
+58.14%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0%
ARK Genomic Revolution ETF
0%
iShares Micro-Cap ETF
佔比0%
ARK Genomic Revolution ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
公告日期
類型
比率
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
